May 8th 2024
A nurse-driven, verbal workflow to place tocilizumab orders contributed to safer and more effective delivery of tocilizumab for cytokine release syndrome.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Extended-Release Anti-CINV Agent Effective in Patients Treated With Cisplatin
March 22nd 2016Findings from a randomized trial reported at the 2016 Annual Meeting of the Society of Gynecologic Oncology showed that APF530, an extended-release formulation of the antiemetic granisetron, achieved a complete response more often than did ondansetron in patients receiving highly emetogenic cisplatin-based chemotherapy.
Neurofeedback Relieves Pain of Chemotherapy-Induced Peripheral Neuropathy
March 19th 2016A majority of patients with cancer who undergo chemotherapy experience neuropathy as result of the treatment, and a new study conducted by researchers at The University of Texas MD Anderson Cancer Center suggests that neurofeedback can reduce the pain associated with the condition and improve quality of life.
Talking CINV: Expanded Treatment Options Can Offer Relief
February 17th 2016New agents and formulations have been added to the CINV armamentarium; however, unless patients are encouraged to discuss the problem with their clinicians, their CINV may go unmanaged, causing even greater problems down the road.
CIPN Widespread in Survivors and Leads to More Falls
January 12th 2016Nearly half of all women report symptoms of chemotherapy-induced peripheral neuropathy (CIPN) long after their cancer treatment has ended, and those with the condition have a significantly higher risk of falls, altered walking patterns, and other difficulties in physical functioning, a new study has found.
Rudolph Navari on Olanzapine for Preventing Nausea and Vomiting
October 12th 2015Rudolph Navari, professor of Medicine at Indiana University School of Medicine - South Bend, discusses the effectiveness of olanzapine (Zyprexa) in preventing nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Relieving Nausea With Olanzapine in Patients Treated for Head and Neck Cancer
June 18th 2015Nausea and vomiting associated with anticancer therapies continue to be among patients' most troubling symptoms. Findings of a clinical trial found that olanzapine demonstrated comparative benefits in relieving these symptoms.
Deborah Watkins Bruner on Side Effects From Platinum-Based Drugs in Ovarian Cancer
June 17th 2015Deborah Watkins Bruner, PhD, RN, FAAN, from the Nell Hodgson Woodruff School of Nursing at Emory University, discusses side effects associated with platinum-based drugs for the treatment of ovarian cancer.